Eva M. Ciruelos, MD, PhD, on HER2-Positive and PAM50 Luminal Breast Cancer: Primary Results From the PATRICIA Trial
2024 ASCO Annual Meeting
Eva M. Ciruelos, MD, PhD, of Spain’s Hospital 12 de Octubre and the Instituto de Investigación Sanitaria Hospital 12 de Octubre, discusses phase II data showing that the combination of palbociclib, trastuzumab, and endocrine therapy improved progression-free survival in patients with previously treated PAM50 luminal A or B, HER2-positive advanced breast cancer, as compared with treatment of physicians’ choice (Abstract 1008).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We presented the first primary results of the PATRICIA cohort C trial. This is an open level, phase two randomized trial that recruited HER2-positive advanced breast cancer patients who received an experimental combination consisted on palbociclib, trastuzumab and endocrine therapy versus treatment of physician choice with T-DM1 or the combination of trastuzumab chemotherapy or endocrine treatment.
These patients were pre-treated patients, at least two prior lines of treatment, and all of them were selected based on the intrinsic subtyping. Just luminal A and luminal B tumors were included in this trial.
Primary result was achieved and progression for survival was significantly improved with combination of palbociclib trastuzumab endocrine treatment over treatment of physician's choice, with a reduction in the risk of progression of about 48%, which is statistically significant. These results are unique as we try to select patients based on a new biomarker, which is intrinsic subtype, and offering this non-chemotherapy combination for these patients that harbored about 50% within the HER-positive HER2-positive disease.
Regarding tolerability, no dose reductions were done differently from these two arms and no dose discontinuations were needed in the experimental arm. That is why our conclusions says that this is a new way to classify in patients within the HER2-positive disease. This is a non-chemo alternative for these patients that will translate, for sure, into quality of life. But still we should validate our results as our trial had some limitations due to a small sample size, so maybe new prospective randomized designs will be needed to confirm our [inaudible 00:02:21] results.
The ASCO Post Staff
Reshma Jagsi, MD, DPhil, of Emory University Winship Cancer Institute, and Tarah J. Ballinger, MD, of Indiana University Simon Comprehensive Cancer Center, discuss the disparate burden of taxane-induced peripheral neuropathy in Black women with early-stage breast cancer and how a tailored trial for this population showed that using docetaxel as the preferred taxane may be beneficial (LBA503).
The ASCO Post Staff
Peter Riedell, MD, of The University of Chicago, discusses phase III findings on the regimen of brentuximab vedotin in combination with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This therapy demonstrated a survival advantage in the third-line setting, but as this is an interim analysis, questions remain regarding long-term safety and duration of response, according to Dr. Riedell (Abstract LBA7005).
The ASCO Post Staff
Toni K. Choueiri, MD, FASCO, of the Dana-Farber Cancer Institute, discusses phase III findings showing that, in patients with advanced renal cell carcinoma (RCC), the benefit of lenvatinib plus pembrolizumab vs sunitinib in overall response rate does not appear to be affected by such factors as gene‐expression signatures for tumor‐induced proliferation, PD‐L1 status, or the mutation status of RCC driver genes.
The ASCO Post Staff
Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses the ongoing phase III BELLWAVE-010 study of nemtabrutinib plus venetoclax vs venetoclax plus rituximab in previously treated patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) (Abstract TPS7089).
The ASCO Post Staff
Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, reports the results from the phase II SACI-IO trial in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who received sacituzumab govitecan-hziy with or without pembrolizumab (LBA1004).